Back to top

Image: Bigstock

McKesson Corporation

Read MoreHide Full Article

McKesson recently announced a multi-year strategic growth initiative update to generate approximately $300 million to $400 million in annual pre-tax gross savings. The company has been riding on Medical-Surgical Solutions segment. The improvement in the company’s international sales is a major positive. Furthermore, management is optimistic about the recent acquisition of Medical Specialties Distributors. On the flip side, dull performance in the European Pharmaceutical Solutions segment is a headwind. McKesson’s escalating operating expenses are concerns. Regulatory headwinds in the United Kingdom and Canada have been strong deterrents in the U.S. Pharmaceutical and Specialty Solutions segment. Price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space add to the company’s woes. McKesson underperformed the industry in a year’s time.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


McKesson Corporation (MCK) - free report >>